Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma

Abstract Aim of the study Gleason score (GS) 3 + 4 = 7 prostate cancer patients with presence of cribriform or intraductal carcinoma (7+ ) have a worse disease-specific survival than those without. The aim of this study was to compare the clinicopathologic characteristics and patient outcomes of men...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2016-10, Vol.66, p.26-33
Main Authors: Kweldam, Charlotte F, Kümmerlin, Intan P, Nieboer, Daan, Verhoef, Esther I, Steyerberg, Ewout W, Incrocci, Luca, Bangma, Chris H, van der Kwast, Theodorus H, Roobol, Monique J, van Leenders, Geert J
Format: Article
Language:English
Subjects:
Age of Onset
Aged
Cribriform
Disease-Free Survival
Early Detection of Cancer
Hematology, Oncology and Palliative Medicine
Humans
Image-Guided Biopsy
Intraductal carcinoma
Male
Middle Aged
Neoplasm Grading
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - pathology
Netherlands - epidemiology
Prostate - pathology
Prostate cancer
Prostate-Specific Antigen - metabolism
Prostatectomy - statistics & numerical data
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aim of the study Gleason score (GS) 3 + 4 = 7 prostate cancer patients with presence of cribriform or intraductal carcinoma (7+ ) have a worse disease-specific survival than those without. The aim of this study was to compare the clinicopathologic characteristics and patient outcomes of men with biopsy GS 3 + 4 = 7 without cribriform or intraductal carcinoma (7– ) to those with GS 3 + 3 = 6. Materials and methods We included all patients from the first screening round of the European Randomized Study of Screening for Prostate Cancer (1993–2000) with a revised GS ≤ 3 + 4 = 7 (n = 796) following the 2014 International Society of Urological Pathology criteria. Relations with biochemical recurrence after radical prostatectomy or radiotherapy were analysed using log-rank testing and multivariable Cox regression analysis. Results In total, 486 patients had GS 6 and 310 had GS 7, 54 of whom had GS 7+ (17%). During a median follow-up of 15 years, biochemical recurrence was seen in 61 (20%) GS 6, 54 (21%) GS 7– and 22 (41%) GS 7+ patients (41%). Both biopsy GS 7– and 7+ patients had significantly higher prostate-specific antigen levels, mean tumour percentage, percentage of positive cores and ≥cT3 than those with GS 6 (all P 
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2016.07.012